Literature DB >> 12655076

Neutralizing epitopes specific for influenza B virus Yamagata group strains are in the 'loop'.

Naoko Nakagawa1, Ritsuko Kubota2, Toshimasa Nakagawa3, Yoshinobu Okuno2.   

Abstract

To study the neutralizing epitopes of influenza B virus Yamagata group strains, two monoclonal antibodies (mAbs) were used to select escape mutants of the virus. mAbs 5H4 and 3A12 were found to react with B/Yamagata group strains in haemagglutination inhibition and neutralization tests; no reactivity with B/Victoria group strains was observed. Most of the mutants reacted poorly to polyclonal ferret antibody against the 1998 isolate. Analysis of the deduced amino acid sequences identified a single amino acid substitution at residue 141 (Gly-->Arg) or 149 (Arg-->Gly) in 5H4-escape mutants and 141 (Gly-->Arg), 147 (Thr-->Ile) or 148 (Ser-->Gly) in 3A12-escape mutants. These residues are situated in close proximity in the 'loop' of the haemagglutinin molecule. These epitopes have been conserved in B/Yamagata group strains for almost 10 years in Japan but amino acid substitutions in the loop have been observed in clinical isolates only since 1999.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655076     DOI: 10.1099/vir.0.18756-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Variation of the conserved neutralizing epitope in influenza B virus victoria group isolates in Japan.

Authors:  Naoko Nakagawa; Ritsuko Kubota; Yoshinobu Okuno
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Discovery of the neutralizing epitope common to influenza B virus victoria group isolates in Japan.

Authors:  Naoko Nakagawa; Jun Suzuoki; Ritsuko Kubota; Shinzo Kobatake; Yoshinobu Okuno
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

3.  Cocirculation of antigenic variants and the vaccine-type virus during the 2004-2005 influenza B virus epidemics in Japan.

Authors:  Naoko Nakagawa; Natsumi Higashi; Toshimasa Nakagawa
Journal:  J Clin Microbiol       Date:  2008-12-17       Impact factor: 5.948

4.  Structural basis for the divergent evolution of influenza B virus hemagglutinin.

Authors:  Fengyun Ni; Elena Kondrashkina; Qinghua Wang
Journal:  Virology       Date:  2013-08-27       Impact factor: 3.616

5.  Substitutions near the HA receptor binding site explain the origin and major antigenic change of the B/Victoria and B/Yamagata lineages.

Authors:  Miruna E Rosu; Pascal Lexmond; Theo M Bestebroer; Blake M Hauser; Derek J Smith; Sander Herfst; Ron A M Fouchier
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-10       Impact factor: 12.779

6.  Influenza B virus victoria group with a new glycosylation site was epidemic in Japan in the 2002-2003 season.

Authors:  Naoko Nakagawa; Ritsuko Kubota; Akiko Maeda; Yoshinobu Okuno
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  Heterogeneous selective pressure acting on influenza B Victoria- and Yamagata-like hemagglutinins.

Authors:  Baltazar Nunes; Pedro Pechirra; Anabela Coelho; Carlos Ribeiro; Ana Arraiolos; Helena Rebelo-de-Andrade
Journal:  J Mol Evol       Date:  2008-10-08       Impact factor: 2.395

8.  Diversifying selective pressure on influenza B virus hemagglutinin.

Authors:  Jun Shen; Brian D Kirk; Jianpeng Ma; Qinghua Wang
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

9.  Crystal structure of unliganded influenza B virus hemagglutinin.

Authors:  Qinghua Wang; Feng Cheng; Mingyang Lu; Xia Tian; Jianpeng Ma
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial.

Authors:  Serge Durviaux; John Treanor; Jiri Beran; Xavier Duval; Meral Esen; Gregory Feldman; Sharon E Frey; Odile Launay; Geert Leroux-Roels; Janet E McElhaney; Andrzej Nowakowski; Guillermo M Ruiz-Palacios; Gerrit A van Essen; Lidia Oostvogels; Jeanne-Marie Devaster; Karl Walravens
Journal:  Clin Vaccine Immunol       Date:  2013-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.